Search
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Viper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalLumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.
Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Fulzerasib
go.drugbank.com/drugs/DB21609InvestigationalFulzerasib has a monoisotopic molecular weight of 630.22 Da. … NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small
Limaprost
go.drugbank.com/drugs/DB09211InvestigationalProstaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. … The drug has been sold under the trade name of Opalmon® Tablets by Ono and Prorenal® Tablets by DSP.
Mephenesin
go.drugbank.com/drugs/DB13583ApprovedWithdrawnMephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression . It first entered use in the 1950s.
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Seliciclib
go.drugbank.com/drugs/DB06195InvestigationalDeveloped by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.